Sclerostin Antikörper (N-Term)
Kurzübersicht für Sclerostin Antikörper (N-Term) (ABIN358751)
Target
Alle Sclerostin (SOST) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- This antibody reacts to SOST.
-
Aufreinigung
- Protein A column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human SOST.
-
Isotyp
- Ig Fraction
-
-
-
-
Applikationshinweise
-
ELISA: 1/1,000. Western blotting: 1/50 - 1/100. Immunohistochemistry: 1/10 - 1/50.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
-
: "Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin." in: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Vol. 31, Issue 10, pp. 1791-1802, (2016) (PubMed).
-
: "Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin." in: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Vol. 31, Issue 10, pp. 1791-1802, (2016) (PubMed).
-
- Sclerostin (SOST)
-
Andere Bezeichnung
- Sclerostin / SOST
-
Hintergrund
- Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
-
Gen-ID
- 50964, 9606
-
UniProt
- Q9BQB4
Target
-